TOBI — Medica
management of cystic fibrosis in patients with Pseudomonas aeruginosa
Preferred products
- tobramycin inhalation solution (generics to Bethkis, TOBI, Kitabis Pak)
- TOBI Podhaler
Initial criteria
- Patient meets the respective standard Prior Authorization Policy criteria for a Non-Preferred Product
- Patient has tried at least one Preferred Product (tobramycin inhalation solution [generics to Bethkis, TOBI, or Kitabis Pak] or TOBI Podhaler) prior to approval of a Non-Preferred Product unless directed to Preferred Product
Approval duration
1 year